PULMATRIX, INC. Net Fee Amt
PULMATRIX, INC. (PULM) had Net Fee Amt of $0.1 as of 2026-07-09, per its S-4 filed 2026-07-09.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-09
- 2026-07-09: Net Fee Amt $0.10.
- 2026-06-04: Net Fee Amt $91.18.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-09 | $0.10 S-4 · filed 2026-07-09 |
| 2026-06-04 | $91.18 S-3 · filed 2026-06-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |